Dickson KA - Search Results

1

SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling.

Field NR, Dickson KA, Nassif NT, Marsh DJ. Field NR, et al. Among authors: dickson ka. Cancer Lett. 2024 Nov 28;605:217282. doi: 10.1016/j.canlet.2024.217282. Epub 2024 Oct 4. Cancer Lett. 2024. PMID: 39369768 Free article. Review.

2

Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer.

Marsh DJ, Ma Y, Dickson KA. Marsh DJ, et al. Among authors: dickson ka. Cancers (Basel). 2020 Nov 20;12(11):3462. doi: 10.3390/cancers12113462. Cancers (Basel). 2020. PMID: 33233707 Free PMC article. Review.

3

Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.

Ma Y, Field NR, Xie T, Briscas S, Kokinogoulis EG, Skipper TS, Alghalayini A, Sarker FA, Tran N, Bowden NA, Dickson KA, Marsh DJ. Ma Y, et al. Among authors: dickson ka. Cancers (Basel). 2024 Sep 3;16(17):3068. doi: 10.3390/cancers16173068. Cancers (Basel). 2024. PMID: 39272926 Free PMC article. Review.

4

Writing Histone Monoubiquitination in Human Malignancy-The Role of RING Finger E3 Ubiquitin Ligases.

Marsh DJ, Dickson KA. Marsh DJ, et al. Among authors: dickson ka. Genes (Basel). 2019 Jan 18;10(1):67. doi: 10.3390/genes10010067. Genes (Basel). 2019. PMID: 30669413 Free PMC article. Review.

5

Ubiquitin chromatin remodelling after DNA damage is associated with the expression of key cancer genes and pathways.

Cole AJ, Dickson KA, Liddle C, Stirzaker C, Shah JS, Clifton-Bligh R, Marsh DJ. Cole AJ, et al. Among authors: dickson ka. Cell Mol Life Sci. 2021 Feb;78(3):1011-1027. doi: 10.1007/s00018-020-03552-5. Epub 2020 May 26. Cell Mol Life Sci. 2021. PMID: 32458023 Free PMC article.

6

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.

Dickson KA, Xie T, Evenhuis C, Ma Y, Marsh DJ. Dickson KA, et al. Int J Mol Sci. 2021 Aug 7;22(16):8506. doi: 10.3390/ijms22168506. Int J Mol Sci. 2021. PMID: 34445211 Free PMC article.

7

An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles.

Joshi N, Liu D, Dickson KA, Marsh DJ, Ford CE, Stenzel MH. Joshi N, et al. Among authors: dickson ka. J Mater Chem B. 2021 Nov 17;9(44):9123-9135. doi: 10.1039/d1tb01837j. J Mater Chem B. 2021. PMID: 34676865

8

Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.

Yee C, Dickson KA, Muntasir MN, Ma Y, Marsh DJ. Yee C, et al. Among authors: dickson ka. Front Bioeng Biotechnol. 2022 Feb 10;10:836984. doi: 10.3389/fbioe.2022.836984. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35223797 Free PMC article. Review.

9

The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells.

Liu D, Kaufmann GF, Breitmeyer JB, Dickson KA, Marsh DJ, Ford CE. Liu D, et al. Among authors: dickson ka. Pharmaceutics. 2022 Apr 11;14(4):837. doi: 10.3390/pharmaceutics14040837. Pharmaceutics. 2022. PMID: 35456672 Free PMC article.

10

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Xie T, Dickson KA, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ. Xie T, et al. Among authors: dickson ka. Cancers (Basel). 2022 Sep 23;14(19):4621. doi: 10.3390/cancers14194621. Cancers (Basel). 2022. PMID: 36230543 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters